PREDICTORS OF ATHEROSCLEROTIC PLAQUE DESTABILIZATION AND THE POSSIBILITY OF ITS CORRECTION-Reference-Cited by-同舟云学术

PREDICTORS OF ATHEROSCLEROTIC PLAQUE DESTABILIZATION AND THE POSSIBILITY OF ITS CORRECTION

Published:2023-12-30 Issue:4 Volume:19 Page:55-62
ISSN:2664-4738
Container-title:Medical Science of Ukraine (MSU)
language:
Short-container-title:Med. Sci. of Ukr.

Author:

Lyzogub V.^ORCID,Motsak T.^ORCID,Savchuk O.^ORCID,Kupchynska O.^ORCID,Kuzmenko L.^ORCID,Galych V-S.^ORCID,Novik D.^ORCID

Abstract

Background. The prevalence and negative impact of generalized atherosclerosis (GAS) on the prognosis of patients necessitates the search for drugs that can slow down the progression of the process Aim: to propose a complex of drugs capable of increasing the stability of atherosclerotic plaques in patients with GAS Materials and methods. 58 men with GAS aged (67.7±4.3) years. Patients. divided into two groups: GAS-1 (n=32) with an ischemic stroke suffered more than a year ago and GAS-2 (n=26) with post-infarction cardiosclerosis. All patients had clinical manifestations of intermittent claudication. The control group consisted of 18 practically healthy men of similar age. The following were studied: the ankle-brachial index, walking distances, blood levels of MMP-2 and MMP-9, indicators of speed and volume of blood flow in three arteries (by the Doppler method), Holter ECG monitoring. After the initial examination against the background of basic therapy, which included statins, beta-blockers, ACE inhibitors or ARBs, antiplatelet agents, patients of GAS-1 and GAS-2 groups were additionally prescribed C (50 mg twice a day) and GABA (250 mg twice a day ). Re-examination was carried out after 12 weeks of complex treatment. Results. We found significantly (p<0.01) higher levels of MMP-2 and MMP-9 in both groups of GAS and significantly (p<0.001) lower values of volumetric blood flow (VF) in all studied vascular pools compared to CG. Adding С and GABA to the standard therapy contributed to a significant (p<0.05) increase in VF indicators in all studied arteries, improvement in cerebral, coronary and peripheral clinical symptoms and a significant decrease in MMP-2 in both groups of GAS: by 22.2% (p <0.05) in the GAS-1 group and by 33.3% (p<0.01) in the GAS-2 group, and in 62.3% of GAS-2 patients, MMP-2 values reached the reference values; in addition, MMP-9 content also decreased significantly (by 15.8%; p<0.05). Conclusion. The obtained data indicate the expediency of using C and GABA as part of complex therapy in patients with GAS to reduce the level of MMP-2, as one of the important factors of destabilization of vulnerable atherosclerotic plaques. It is important to continue the search for pharmaceutical drugs capable of positively influencing the level of MMP-9.

Publisher

Bogomolets National Medical University

Reference16 articles.

1. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgözoğlu L, Lewis EF. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. DOI: 10.1038/s41572-019-0106-z.

2. Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Rev Esp Cardiol (Engl Ed). 2018;71(2):111. English, Spanish. DOI: 10.1016/j.rec.2017.12.014.

3. Spacek M, Zemanek D, Hutyra M, Sluka M, Taborsky M. Vulnerable atherosclerotic plaque - a review of current concepts and advanced imaging. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018;162(1):10-17. DOI: 10.5507/bp.2018.004.

4. Picano E, Paterni M. Ultrasound tissue characterization of vulnerable atherosclerotic plaque. Int J Mol Sci. 2015;16(5):10121-33. DOI: 10.3390/ijms160510121.

5. Wang X, Khalil RA. Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. Adv Pharmacol. 2018;81:241-330. DOI: 10.1016/bs.apha.2017.08.002.